Plaintiffs’ law firm Block & Leviton announced today that it has reached a $55 million settlement with Celgene in a class action case, “In re Thalomid and Revlimid Antitrust Litigation.“
- Filed in 2014, plaintiffs in class lawsuit alleged that Celgene monopolized the market for Thalomid and Revlimid, used primarily to treat multiple myeloma
- Specifically, plaintiffs alleged Celgene kept generic versions of two drugs off market,
- Parties agreed to resolve case after close of discovery and during pendency of plaintiffs’ motion to certify class
Link to Statement: Block & Leviton Announces $55 Million Settlement in Antitrust Case Against Celgene
©2019 Bloomberg ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.